PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities

FEBS Letters

Volumn 584, Issue 4, 2010, Pages 701-706

  Mbikay, Majambu ^a,b,c   Sirois, Francine ^a   Mayne, Janice ^a   Wang, Gen Sheng ^a   Chen, Andrew ^a   Dewpura, Thilina ^a   Prat, Annik ^d   Seidah, Nabil G ^d   Chretien, Michel ^a,b,c   Scott, Fraser W ^a,b,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Cholesterol; Glucose; Pancreatic islet beta cell; Proprotein convertase

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENE EXPRESSION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HYPERGLYCEMIA; HYPOINSULINEMIA; INFLAMMATION; MALE; MOUSE; NONHUMAN; NULL ALLELE; PANCREAS ISLET; PANCREAS ISLET DISEASE; PANCREAS MALFORMATION; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BLOTTING, WESTERN; FEMALE; GENE EXPRESSION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; RECEPTORS, LDL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE ENDOPEPTIDASES; TISSUE CULTURE TECHNIQUES;

MUS;

EID: 77649274263     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.12.018     Document Type: Article

References (27)

1. Seidah N.G., Mayer G., Zaid A., Rousselet E., Nassoury N., Poirier S., Essalmani R., Prat A. The activation and physiological functions of the proprotein convertases. Int. J. Biochem. Cell Biol. 2008, 40:1111-1125.
2. Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., Basak A., Prat A., Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA 2003, 100:928-933.
3. Zaid A., Roubtsova A., Essalmani R., Marcinkiewicz J., Chamberland A., Hamelin J., Tremblay M., Jacques H., Jin W., Davignon J., Seidah N.G., Prat A. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008, 48:646-654.
4. Maxwell K.N., Fisher E.A., Breslow J.L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. USA 2005, 102:2069-2074.
5. Cameron J., Holla O.L., Ranheim T., Kulseth M.A., Berge K.E., Leren T.P. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 2006, 15:1551-1558.
6. Nassoury N., Blasiole D.A., Tebon Oler A., Benjannet S., Hamelin J., Poupon V., McPherson P.S., Attie A.D., Prat A., Seidah N.G. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 2007, 8:718-732.
7. Rashid S., Curtis D.E., Garuti R., Anderson N.N., Bashmakov Y., Ho Y.K., Hammer R.E., Moon Y.A., Horton J.D. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA 2005, 102:5374-5379.
8. Maxwell K.N., Breslow J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA 2004, 101:7100-7105.
9. Park S.W., Moon Y.A., Horton J.D. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 2004, 279:50630-50638.
10. Lalanne F., Lambert G., Amar M.J., Chetiveaux M., Zair Y., Jarnoux A.L., Ouguerram K., Friburg J., Seidah N.G., Brewer H.B., Krempf M., Costet P. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J. Lipid Res. 2005, 46:1312-1319.
11. Lambert G., Jarnoux A.L., Pineau T., Pape O., Chetiveaux M., Laboisse C., Krempf M., Costet P. Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr. Endocrinology 2006, 147:4985-4995.
12. Lagace T.A., Curtis D.E., Garuti R., McNutt M.C., Park S.W., Prather H.B., Anderson N.N., Ho Y.K., Hammer R.E., Horton J.D. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 2006, 116:2995-3005.
13. Grupping A.Y., Cnop M., Van Schravendijk C.F., Hannaert J.C., Van Berkel T.J., Pipeleers D.G. Low density lipoprotein binding and uptake by human and rat islet beta cells. Endocrinology 1997, 138:4064-4068.
14. Roehrich M.E., Mooser V., Lenain V., Herz J., Nimpf J., Azhar S., Bideau M., Capponi A., Nicod P., Haefliger J.A., Waeber G. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J. Biol. Chem. 2003, 278:18368-18375.
15. Cnop M., Hannaert J.C., Grupping A.Y., Pipeleers D.G. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 2002, 143:3449-3453.
16. Schmidt G., Sirois F., Anini Y., Kauri L.M., Gyamera-Acheampong C., Fleck E., Scott F.W., Chretien M., Mbikay M. Differences of pancreatic expression of 7B2 between C57BL/6J and C3H/HeJ mice and genetic polymorphisms at its locus (Sgne1). Diabetes 2006, 55:452-459.
17. Huang L., Shen H., Atkinson M.A., Kennedy R.T. Detection of exocytosis at individual pancreatic beta cells by amperometry at a chemically modified microelectrode. Proc. Natl. Acad. Sci. USA 1995, 92:9608-9612.
18. Holland P.M., Abramson R.D., Watson R., Gelfand D.H. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc. Natl. Acad. Sci. USA 1991, 88:7276-7280.
19. Wang G.S., Rosenberg L., Scott F.W. Tubular complexes as a source for islet neogenesis in the pancreas of diabetes-prone BB rats. Lab. Invest. 2005, 85:675-688.
20. Ishikawa M., Iwasaki Y., Yatoh S., Kato T., Kumadaki S., Inoue N., Yamamoto T., Matsuzaka T., Nakagawa Y., Yahagi N., Kobayashi K., Takahashi A., Yamada N., Shimano H. Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity. J. Lipid Res. 2008, 49:2524-2534.
21. Brunham L.R., Kruit J.K., Pape T.D., Timmins J.M., Reuwer A.Q., Vasanji Z., Marsh B.J., Rodrigues B., Johnson J.D., Parks J.S., Verchere C.B., Hayden M.R. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 2007, 13:340-347.
22. Risbud M.V., Bhonde R.R. Models of pancreatic regeneration in diabetes. Diabetes Res. Clin. Pract. 2002, 58:155-165.
23. Franconi F., Seghieri G., Canu S., Straface E., Campesi I., Malorni W. Are the available experimental models of type 2 diabetes appropriate for a gender perspective?. Pharmacol. Res. 2008, 57:6-18.
24. Macotela Y., Boucher J., Tran T.T., Kahn C.R. Sex and depot differences in adipocyte insulin sensitivity and glucose metabolism. Diabetes 2009, 58:803-812.
25. Le May C., Chu K., Hu M., Ortega C.S., Simpson E.R., Korach K.S., Tsai M.J., Mauvais-Jarvis F. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc. Natl. Acad. Sci. USA 2006, 103:9232-9237.
26. Abifadel M., Rabes J.P., Devillers M., Munnich A., Erlich D., Junien C., Varret M., Boileau C. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum. Mutat. 2009, 30:520-529.
27. Franzblau A., Criqui M.H. Characteristics of persons with marked hypocholesterolemia. A population-based study. J. Chronic Dis. 1984, 37:387-395.